Bollard Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bollard Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-400	Closed	-$31K	–	303
2022 Q1	$31K	Hold	400	–	–	﹤0.01%	371
2021 Q4	$35K	Hold	400	–	–	﹤0.01%	370
2021 Q3	$31K	Hold	400	–	–	﹤0.01%	375
2021 Q2	$33K	Hold	400	–	–	﹤0.01%	369
2021 Q1	$30K	Hold	400	–	–	﹤0.01%	376
2020 Q4	$35K	Hold	400	–	–	﹤0.01%	361
2020 Q3	$30K	Hold	400	–	–	﹤0.01%	358
2020 Q2	$49K	Buy	+400	New	+$39.8K	﹤0.01%	343

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bollard Group's BMRN Position: Q2 2022 in Review

Bollard Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 400 shares — an estimated $31K sold.

Bollard Group first reported a position in BMRN in Q2 2020 and held it in 8 quarters. The position peaked at $49K in Q2 2020. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Bollard Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Bollard Group sold 400 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $31K.
Bollard Group first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Bollard Group's BioMarin Pharmaceuticals position peaked at $49K in Q2 2020.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.